Clinical Trial Goal
To find out:
- The highest dose of AZD4512 that’s safe to give
- If AZD4512 is safe and works well to treat B-NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have B-cell NHL. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Waldenström macroglobulinemia
- Do not have untreated lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
AZD4512 is an antibody-drug conjugate, or combination, that targets CD22 on certain cells.
You’ll get:
You’ll get:
- AZD4512 – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 1 month. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved AZD4512.
Contacts
AstraZeneca Clinical Study Information Center, 1-877-240-9479, information.center@astrazeneca.com
Locations
Sponsors
lead: AstraZeneca
